Cord blood banking: what the data actually shows

In the third trimester, somewhere between the hospital tour and the car-seat install, a brochure usually appears. Glossy. Smiling baby. A sentence about 'biological insurance' and a phone number. The pitch is that for a one-time fee in the $1,500–$3,000 range, plus around $200 a year forever, you can preserve your newborn's stem cells against a future you can't predict.

It is one of the more expensive decisions a new parent is asked to make on a tight timeline, and the marketing language carefully blurs the line between what cord blood stem cells can definitively do today and what they might do someday. This piece walks through what the cells actually are, what the established uses are, what the honest probability of using them is, what the major American Academy of Pediatrics statement says about private banking, and how the four big US private banks compare.

What is actually in cord blood

Cord blood — the blood left in the umbilical cord and placenta after delivery — is rich in hematopoietic stem cells, or HSCs. These are the cells that build and replenish the blood and immune system: red cells, white cells, platelets. They are the same kind of cell harvested from bone marrow or peripheral blood for adult stem cell transplants. They are real, they work, and HSCT (hematopoietic stem cell transplantation) is a mature, established treatment for a defined set of diseases.

Here is what they are not: they are not pluripotent stem cells. They cannot become any tissue in the body. The marketing language around 'regenerative medicine' and 'future therapies' frequently leans on the public confusion between HSCs (lineage-restricted, well understood, currently used) and the broader category of stem cells that includes embryonic and induced pluripotent cells (which is where most of the futuristic press happens). Cord blood is not a source of those.

Cord tissue — the umbilical cord itself, banked separately by most private banks for an additional fee — contains mesenchymal stem cells (MSCs). MSCs can differentiate into bone, cartilage, and connective tissue in the lab and have anti-inflammatory properties that have made them an active area of research. ViaCord's own legal disclaimer states it cleanly: cord tissue stem cells have not been used in treatment yet; research is ongoing. Banking cord tissue is buying lottery tickets on therapies that may or may not exist in your child's lifetime — most cord tissue claims sit in the speculative column.

What cord blood is actually used for

The FDA and the major transplant registries recognize cord blood HSCs as a treatment option for roughly 80 conditions. The list is real but specific:

• Leukemias and lymphomas (ALL, AML, Hodgkin's and non-Hodgkin's, others)
• Inherited immune disorders (SCID, Wiskott-Aldrich, others)
• Inherited red blood cell disorders (sickle cell disease, beta thalassemia)
• Some inherited metabolic disorders (Hurler syndrome, Krabbe, others)
• Bone marrow failure syndromes (aplastic anemia, Fanconi anemia)

The list is the same list as for adult bone marrow transplants — because cord blood is a source of the same cells. What it is not on the list for: autism, cerebral palsy, type 1 diabetes, Alzheimer's, spinal cord injury, or any of the regenerative-medicine applications private banks gesture toward in their patient stories. There are clinical trials in some of these areas (cerebral palsy in particular has had several small trials), but "in trials" is not the same as "works."

The probability your child will ever use their own banked cord blood

This is the load-bearing number, and it is the number private banks are quietest about. The estimated lifetime probability that a child will use their own privately banked cord blood is somewhere between 1 in 20,000 and 1 in 200,000 (Sun et al., 2010, Transfusion). The American Academy of Pediatrics 2017 policy statement (Shearer et al., Pediatrics 140(5):e20172695) cites figures in the same range and concludes — explicitly — that private storage of cord blood as biological insurance against unforeseeable future need is unwise unless there is a family member with a current or potential need to undergo a stem cell transplant.

Why so unlikely? Two reasons. First, the diseases cord blood treats are individually rare. Second, and more importantly, in the diseases where cord blood is most useful — leukemias, especially — autologous transplant (using the patient's own cells) is often the wrong treatment. The leukemia originated in the patient's own hematopoietic system. Putting back the same line of cells that produced the cancer can put back the genetic predisposition that caused it. Allogeneic transplant from a matched donor is generally preferred. So the very stem cells you banked at birth are often not the cells your child would actually receive.

There are exceptions. If a child has a sibling with a condition treatable by HSCT, the new baby's cord blood may be a useful matched donor source — and this is the one situation the AAP and most pediatric hematologists actively support private (or directed) banking. Some banks offer free or reduced-cost "directed donation" programs for families in this situation; CBR, ViaCord, and others all run such programs and they are worth asking about explicitly.

Public banking — the option that gets less marketing budget

Public cord blood donation is free. You give up ownership; the cord blood enters the National Marrow Donor Program / Be The Match registry, where it becomes available to any matched patient who needs it. The unit will be HLA-typed, characterized, and listed alongside the roughly 250,000 cord blood units in the US public inventory.

Roughly 80% of cord blood transplants performed in the US use units from unrelated donors via the public registry — not from privately banked autologous units. From a public-health perspective, the public banks are doing the work; the private banks are mostly storing units that are statistically unlikely to ever be used. If your hospital participates in public collection (a minority of US hospitals do, mostly large academic centers), donating is the option with the largest expected benefit, and the cost to you is zero.

The catch: public collection is only available at certain hospitals. If you want to donate publicly, you need to register early (often by 28–34 weeks) through the NMDP at nmdp.org or through hospital-affiliated programs like StemCyte and the New York Blood Center's National Cord Blood Program.

The AAP position, in its own words

The AAP's 2017 policy statement (reaffirmed in 2020) is the most cited single document in this field. The headline language: private storage of cord blood as biological insurance against future unforeseen need is unwise. Private banking is supported only when an older sibling has a condition treatable by HSCT, or when there is a known parental genetic condition that may require sibling transplantation.

Two things to notice about the AAP framing. First, it is unusually direct for a medical-society policy document — "unwise" is a strong word in this register. Second, it is not anti-cord-blood. The AAP supports public donation, supports directed donation when there is a family member with a treatable condition, and supports continued research. What it pushes back against is the speculative-future-use framing that drives most private-bank marketing.

The major US private banks

Four banks dominate the US private market. They differ less than the marketing implies — all four are AABB-accredited, FDA-registered, and use comparable processing technology. The real differences are pricing structure, optional add-ons, and how aggressively they push speculative cord-tissue claims.

• Cord Blood Registry (CBR) — the largest US private bank. Stores cord blood, cord tissue, and (recently) placental tissue. Collection/processing is in the $1,500–$2,500 range; annual storage runs $175–$300 depending on plan. CBR does not publish prices publicly on its site as of 2026 — you have to request a quote, which is itself a useful signal. Strong family-medical-history program for sibling matches.
• ViaCord — owned by Revvity (formerly PerkinElmer). Markets aggressively on "nearly 80 conditions" and bundles genetic testing add-ons (whole genome sequencing, predisposition panels) that materially increase total spend. Prices are gated behind an info-kit request. Their own legal disclaimer explicitly states cord tissue stem cells have not been used in treatment yet — language worth quoting back to a sales rep.
• Cryo-Cell International — publicly traded, oldest of the four, prices on the website. As of mid-2026: cord blood processing $1,486 (standard) or $1,836 (premium); cord blood + tissue $2,442–$2,792. First-year storage $199 (cord blood) or $398 (cord blood + tissue). They also offer 18-year prepaid storage plans and a lifetime plan. Most price-transparent of the four.
• Americord — newer, more aggressive product tiering. Essential Family Plan (cord blood only) starts at $1,078 in year one, scaling up through Advanced (adds cord tissue), Complete (adds placental tissue), Ultimate (adds newborn exosome banking), and Maximum (adds maternal exosome banking) — the last two are essentially research-grade banking sold as consumer products with no current clinical use.

A few honest comparisons across the four:

• On core cord blood banking, the four banks are within a few hundred dollars of each other once you net out promotions. The 18-year total cost of ownership is roughly $4,000–$8,000 depending on add-ons.
• Cord tissue adds $800–$1,500 in upfront cost and roughly doubles annual storage, in exchange for cells that, per the banks' own disclaimers, currently have no FDA-approved clinical use.
• Exosome banking and placental tissue banking are even further down the speculative ladder. There is no clinical reason for a typical family to pay for these; they are revenue diversification for the banks.

When private banking is actually justified

There is a small set of situations where the math flips and private (or directed) banking is genuinely the right call. The clearest:

• An older sibling, parent, or first-degree relative has a condition treatable by HSCT — leukemia, sickle cell, thalassemia, certain immune deficiencies. The cord blood becomes a directed-donor unit for a known recipient.
• A known parental carrier status for an autosomal recessive condition where future siblings may be affected (some metabolic disorders, hemoglobinopathies, certain immune conditions).
• A family ethnicity poorly represented in the public registry, where the odds of finding an unrelated match if needed are materially lower. (This is a real consideration; the public registry is heavily skewed toward European-ancestry donors.)

Outside those situations, the AAP's framing is the one to take seriously: the expected value of private banking for a healthy newborn with no relevant family history is low, and the dollars are usually better spent on disability insurance, a 529, or — frankly — sleep.

What we would actually do

For a family with no relevant history: skip private banking. If your delivery hospital participates in public collection, donate. If not, accept that the cord blood will be discarded as medical waste — which is the outcome for the vast majority of US births already.

For a family with relevant history: talk to a pediatric hematologist before you talk to a sales rep. Many of the major banks offer free or substantially reduced banking when there is a documented sibling or family member with a treatable condition. The pediatric hematology service at your delivery hospital can often connect you directly to a directed-donation program without going through a private bank at all.

Sources

• Shearer WT, et al. Cord Blood Banking for Potential Future Transplantation. AAP Policy Statement. Pediatrics. 2017;140(5):e20172695. (Reaffirmed 2020.)
• Sun J, Allison J, McLaughlin C, et al. Differences in quality between privately and publicly banked umbilical cord blood units. Transfusion. 2010;50(9):1980–1987.
• National Marrow Donor Program / Be The Match (NMDP). Cord blood transplantation overview and public donation registry. nmdp.org.
• American College of Obstetricians and Gynecologists Committee Opinion 771: Umbilical Cord Blood Banking. 2019.
• FDA. Cord Blood Banking — Information for Consumers. fda.gov.
• Cryo-Cell International public pricing, cryo-cell.com/cord-blood-banking-costs (verified 2026).
• Americord public pricing, americordblood.com/pricing (verified 2026).
• ViaCord product disclaimers and service descriptions, viacord.com (verified 2026).
• Cord Blood Registry (CBR) service descriptions, cordblood.com (verified 2026).